TargetBeta
DRD4
dopamine receptor D4 · Dopamine receptors
3 programs in company-led studies act on DRD4, from 3 companies: 0 in phase 3, 3 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Olanzapinerule | Eli Lilly | phase 4 | 761 running | DRD2, DRD3, HTR2A, HTR2C | ChEMBL |
| rotigotinerule | UCB | phase 4 | 641 running | DRD2, DRD3 | ChEMBL |
| Pramipexolerule | Boehringer Ingelheim | phase 4 | 441 running | DRD2, DRD3 | ChEMBL |
Conditions their studies are in
- Parkinson Disease, 2 programs
- Restless Legs Syndrome, 2 programs
- Bipolar Disorder, 1 program
- Borderline Personality Disorder, 1 program
- Depressive Disorder, Major, 1 program
- Depressive Disorder, Treatment-Resistant, 1 program
- Fasting, 1 program
- Fibromyalgia, 1 program
- Obsessive-Compulsive Disorder, 1 program
- Schizophrenia, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2027Olanzapine · Eli Lilly · phase 4 · NCT07565428
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.